Needham Initiates Coverage On Inari Medical with Buy Rating, Announces Price Target of $72
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has initiated coverage on Inari Medical (NASDAQ:NARI) with a Buy rating and set a price target of $72.
January 23, 2024 | 11:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham has initiated coverage on Inari Medical with a Buy rating and a price target of $72.
Analyst ratings, especially from reputable firms like Needham, can significantly influence investor sentiment and stock prices. A Buy rating combined with a price target that suggests upside potential is likely to be viewed positively by the market, potentially leading to a short-term increase in the stock price of Inari Medical.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100